{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-002673","form_type":"8-K","ticker":"ANIK","cik":"0000898437","company_name":"Anika Therapeutics, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.379214+00:00","generated_at":"2026-06-02T15:01:33.080908+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Anika Therapeutics appoints Stephen Griffin as CFO replacing Michael Levitz effective June 3, 2024","bullets":["Stephen Griffin appointed EVP, CFO and Treasurer of Anika Therapeutics, effective June 3, 2024.","Griffin receives $500K base salary, 60% target bonus, and $2M equity grant split between RSUs and stock options.","Michael Levitz resigned as CFO on May 2; will stay through Dec 31, 2024 for transition, receiving $100K one-time payment.","Levitz's separation includes continued salary through year-end and a general release of claims."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-002673","json":"https://secwatch.observer/filing/0001171843-24-002673.json","markdown":"https://secwatch.observer/filing/0001171843-24-002673.md","text":"https://secwatch.observer/filing/0001171843-24-002673.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/898437/000117184324002673/0001171843-24-002673-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/898437/000117184324002673/f8k_050824.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T15:01:33.080908+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c16dd46b3a","claim":"Michael Levitz resigned as Executive Vice President, Chief Financial Officer and Treasurer at Anika Therapeutics, Inc..","evidence_excerpt":"who tendered his resignation on May 2, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184324002673/0001171843-24-002673-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Executive Vice President, Chief Financial Officer and Treasurer"}],"fact_type":"executive_change"},{"claim_id":"c942fdaf52","claim":"Stephen Griffin was appointed as Executive Vice President, Chief Financial Officer and Treasurer at Anika Therapeutics, Inc..","evidence_excerpt":"announced that Stephen Griffin would be joining the Company as its Executive Vice President, Chief Financial Officer and Treasurer, effective June 3, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/898437/000117184324002673/0001171843-24-002673-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Vice President, Chief Financial Officer and Treasurer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}